Lilly spokesman Charles McAtee says the long-acting injectable form of Zyprexa shows a relapse rate comparable to the pill version of the anti-psychotic currently being sold by the Indianapolis company. The new version still must be approved by federal regulators.
Indianapolis-based Lilly presented results of the 24-week study at a medical conference in Barcelona, Spain.
(Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)